Chronic GVHD characteristics at enrollment
| . | Severity at enrollment, N = 298 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mild (N = 32) . | Moderate (N = 175) . | Severe (N = 91) . | |||||||
| n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | |
| Months from transplantation to cGVHD diagnosis | 32 | 7.4 (1.4-23.7) | 175 | 7.2 (2.3-33.3) | 91 | 7.0 (2.0-28.6) | |||
| Months from cGVHD diagnosis to enrollment | 32 | 2.2 (0-31.3) | 175 | 3.3 (0-35.3) | 91 | 2.0 (0-26.9) | |||
| Comorbidities at enrollment | 32 | 2 (0-7) | 175 | 3 (0-9) | 91 | 3 (0-10) | |||
| Type | 32 | 175 | 91 | ||||||
| Incident | 19 (59) | 87 (50) | 53 (58) | ||||||
| Prevalent | 13 (41) | 88 (50) | 38 (42) | ||||||
| Chronic GVHD type | 31 | 158 | 82 | ||||||
| Overlap acute and chronic GVHD | 15 (48) | 66 (42) | 40 (49) | ||||||
| Classic chronic GVHD | 16 (52) | 92 (58) | 42 (51) | ||||||
| Total number of organs involved | 32 | 2 (0-2) | 175 | 3 (1-7) | 91 | 4 (1-7) | |||
| Organs involved | |||||||||
| Skin | 13 (41) | 32 | 105 (60) | 175 | 70 (77) | 91 | |||
| Mouth | 14 (44) | 32 | 113 (65) | 175 | 57 (63) | 91 | |||
| Eye | 3 (9) | 32 | 99 (57) | 175 | 49 (54) | 91 | |||
| Gastrointestinal | 3 (9) | 32 | 49 (28) | 175 | 28 (31) | 91 | |||
| Liver | 13 (41) | 32 | 83 (48) | 173 | 53 (58) | 91 | |||
| Joint | 3 (9) | 32 | 46 (26) | 175 | 29 (32) | 91 | |||
| Genital | 0 (0) | 26 | 23 (14) | 163 | 14 (16) | 89 | |||
| Lung | 0 (0) | 32 | 90 (51) | 175 | 58 (64) | 91 | |||
| Platelet count at onset, 109/L | 32 | 172 | 88 | ||||||
| < 100 | 7 (22) | 39 (23) | 24 (27) | ||||||
| ≥ 100 | 25 (78) | 133 (77) | 64 (73) | ||||||
| Total serum bilirubin, mg/dL | 32 | 0.5 (0.2-2.1) | 171 | 0.6 (0.1-19.7) | 88 | 0.7 (0.3-15.1) | |||
| Karnofsky performance status at enrollment | 26 | 150 | 80 | ||||||
| ≤ 70 | 9 (35) | 45 (30) | 38 (48) | ||||||
| 80 | 4 (15) | 36 (24) | 13 (16) | ||||||
| 90-100 | 13 (50) | 69 (46) | 29 (36) | ||||||
| Unusual manifestations | |||||||||
| Pleural effusion(s) | 0 (0) | 32 | 3 (2) | 175 | 3 (3) | 91 | |||
| Bronchiolitis obliterans syndrome | 0 (0) | 32 | 8 (5) | 175 | 9 (10) | 91 | |||
| COP (formally bronchiolitis obliterans organizing pneumonia) | 1 (3) | 32 | 3 (2) | 175 | 0 (0) | 91 | |||
| Nephrotic syndrome | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Malabsorption | 0 (0) | 32 | 1 (1) | 175 | 0 (0) | 91 | |||
| Esophageal stricture or web | 0 (0) | 32 | 1 (1) | 175 | 1 (1) | 91 | |||
| Ascites (serositis) | 0 (0) | 32 | 1 (1) | 175 | 1 (1) | 91 | |||
| Myasthenia gravis | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Peripheral neuropathy | 1 (3) | 32 | 11 (6) | 175 | 7 (8) | 91 | |||
| Polymyositis | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Pericardial effusion | 0 (0) | 32 | 1 (1) | 175 | 0 (0) | 91 | |||
| Cardiomyopathy | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Cardiac conduction defects | 0 (0) | 32 | 1 (1) | 175 | 2 (2) | 91 | |||
| Coronary artery involvement | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| . | Severity at enrollment, N = 298 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mild (N = 32) . | Moderate (N = 175) . | Severe (N = 91) . | |||||||
| n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | |
| Months from transplantation to cGVHD diagnosis | 32 | 7.4 (1.4-23.7) | 175 | 7.2 (2.3-33.3) | 91 | 7.0 (2.0-28.6) | |||
| Months from cGVHD diagnosis to enrollment | 32 | 2.2 (0-31.3) | 175 | 3.3 (0-35.3) | 91 | 2.0 (0-26.9) | |||
| Comorbidities at enrollment | 32 | 2 (0-7) | 175 | 3 (0-9) | 91 | 3 (0-10) | |||
| Type | 32 | 175 | 91 | ||||||
| Incident | 19 (59) | 87 (50) | 53 (58) | ||||||
| Prevalent | 13 (41) | 88 (50) | 38 (42) | ||||||
| Chronic GVHD type | 31 | 158 | 82 | ||||||
| Overlap acute and chronic GVHD | 15 (48) | 66 (42) | 40 (49) | ||||||
| Classic chronic GVHD | 16 (52) | 92 (58) | 42 (51) | ||||||
| Total number of organs involved | 32 | 2 (0-2) | 175 | 3 (1-7) | 91 | 4 (1-7) | |||
| Organs involved | |||||||||
| Skin | 13 (41) | 32 | 105 (60) | 175 | 70 (77) | 91 | |||
| Mouth | 14 (44) | 32 | 113 (65) | 175 | 57 (63) | 91 | |||
| Eye | 3 (9) | 32 | 99 (57) | 175 | 49 (54) | 91 | |||
| Gastrointestinal | 3 (9) | 32 | 49 (28) | 175 | 28 (31) | 91 | |||
| Liver | 13 (41) | 32 | 83 (48) | 173 | 53 (58) | 91 | |||
| Joint | 3 (9) | 32 | 46 (26) | 175 | 29 (32) | 91 | |||
| Genital | 0 (0) | 26 | 23 (14) | 163 | 14 (16) | 89 | |||
| Lung | 0 (0) | 32 | 90 (51) | 175 | 58 (64) | 91 | |||
| Platelet count at onset, 109/L | 32 | 172 | 88 | ||||||
| < 100 | 7 (22) | 39 (23) | 24 (27) | ||||||
| ≥ 100 | 25 (78) | 133 (77) | 64 (73) | ||||||
| Total serum bilirubin, mg/dL | 32 | 0.5 (0.2-2.1) | 171 | 0.6 (0.1-19.7) | 88 | 0.7 (0.3-15.1) | |||
| Karnofsky performance status at enrollment | 26 | 150 | 80 | ||||||
| ≤ 70 | 9 (35) | 45 (30) | 38 (48) | ||||||
| 80 | 4 (15) | 36 (24) | 13 (16) | ||||||
| 90-100 | 13 (50) | 69 (46) | 29 (36) | ||||||
| Unusual manifestations | |||||||||
| Pleural effusion(s) | 0 (0) | 32 | 3 (2) | 175 | 3 (3) | 91 | |||
| Bronchiolitis obliterans syndrome | 0 (0) | 32 | 8 (5) | 175 | 9 (10) | 91 | |||
| COP (formally bronchiolitis obliterans organizing pneumonia) | 1 (3) | 32 | 3 (2) | 175 | 0 (0) | 91 | |||
| Nephrotic syndrome | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Malabsorption | 0 (0) | 32 | 1 (1) | 175 | 0 (0) | 91 | |||
| Esophageal stricture or web | 0 (0) | 32 | 1 (1) | 175 | 1 (1) | 91 | |||
| Ascites (serositis) | 0 (0) | 32 | 1 (1) | 175 | 1 (1) | 91 | |||
| Myasthenia gravis | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Peripheral neuropathy | 1 (3) | 32 | 11 (6) | 175 | 7 (8) | 91 | |||
| Polymyositis | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Pericardial effusion | 0 (0) | 32 | 1 (1) | 175 | 0 (0) | 91 | |||
| Cardiomyopathy | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
| Cardiac conduction defects | 0 (0) | 32 | 1 (1) | 175 | 2 (2) | 91 | |||
| Coronary artery involvement | 0 (0) | 32 | 0 (0) | 175 | 0 (0) | 91 | |||
cGVHD indicates chronic GVHD; and COP, cryptogeneic organizing pneumonia.